Corcept Therapeutics Inc
XBER:HTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corcept Therapeutics Inc
XBER:HTD
|
US |
|
Q2 Metals Corp
OTC:QUEXF
|
CA |
|
N
|
Nikki Global Finance Ltd
BSE:531272
|
IN |
Corcept Therapeutics Inc
Corcept Therapeutics Inc. is a biopharmaceutical company that has carved out a distinctive niche in the world of medicine by focusing on the development of drugs that modulate the effects of the hormone cortisol. Founded in 1998, the company is headquartered in Menlo Park, California. The real turning point for Corcept came when it developed mifepristone, branded as Korlym, approved by the FDA in 2012 for the treatment of Cushing's syndrome—a rare endocrine disorder characterized by excessive cortisol levels. Korlym works by mitigating the effects of excessive cortisol, providing relief from a range of debilitating symptoms. This first-in-class medication provided Corcept with a foothold in the industry, enabling it to build a sustainable revenue stream from a patient population with significant unmet medical needs.
The business model of Corcept is primarily anchored in its innovative endocrinology portfolio, with a keen focus on expanding its therapeutic applications to other cortisol-related conditions. Beyond Korlym, the company’s pipeline includes an array of selective cortisol modulators aimed at exploring potential treatments for conditions such as antipsychotic-induced weight gain and various forms of cancer. This strategic orientation towards research and development is crucial for Corcept's growth, allowing it to leverage its expertise and proprietary technology to propel further success. Revenues are chiefly generated through the direct sale of Korlym in the United States, with ambitions to broaden its market reach as it seeks regulatory approvals for new indications and territories. This approach not only reinforces its commitment to considerable unmet needs in medicine but also positions Corcept as an influential force in the realm of cortisol modulation therapies.
Corcept Therapeutics Inc. is a biopharmaceutical company that has carved out a distinctive niche in the world of medicine by focusing on the development of drugs that modulate the effects of the hormone cortisol. Founded in 1998, the company is headquartered in Menlo Park, California. The real turning point for Corcept came when it developed mifepristone, branded as Korlym, approved by the FDA in 2012 for the treatment of Cushing's syndrome—a rare endocrine disorder characterized by excessive cortisol levels. Korlym works by mitigating the effects of excessive cortisol, providing relief from a range of debilitating symptoms. This first-in-class medication provided Corcept with a foothold in the industry, enabling it to build a sustainable revenue stream from a patient population with significant unmet medical needs.
The business model of Corcept is primarily anchored in its innovative endocrinology portfolio, with a keen focus on expanding its therapeutic applications to other cortisol-related conditions. Beyond Korlym, the company’s pipeline includes an array of selective cortisol modulators aimed at exploring potential treatments for conditions such as antipsychotic-induced weight gain and various forms of cancer. This strategic orientation towards research and development is crucial for Corcept's growth, allowing it to leverage its expertise and proprietary technology to propel further success. Revenues are chiefly generated through the direct sale of Korlym in the United States, with ambitions to broaden its market reach as it seeks regulatory approvals for new indications and territories. This approach not only reinforces its commitment to considerable unmet needs in medicine but also positions Corcept as an influential force in the realm of cortisol modulation therapies.
Revenue: First-quarter revenue was $164.9 million, up from $157.2 million a year ago, and management raised full-year 2026 revenue guidance to $950 million to $1.05 billion.
Endocrinology growth: Corcept said demand for its Cushing's syndrome medicines is accelerating, with record new prescriptions, record prescribers, and all-time high patient counts, though first-quarter revenue lagged the underlying momentum because of insurance reauthorization delays and a pharmacy transition.
Oncology launch: Lifyorli was approved 3.5 months early for platinum-resistant ovarian cancer, and management said the launch is off to a strong start with more than 200 physicians already writing prescriptions and NCCN preferred status helping access.
Pipeline breadth: The company highlighted relacorilant in Cushing's syndrome, new oncology studies, the Phase II MONARCH trial in MASH, and a planned Phase III ALS study for dazucorilant.
Long-term outlook: Management reiterated ambitious long-term targets, including at least $2 billion in annual revenue for the current Cushing's business by the end of the decade and more than $1 billion annually in U.S. revenue for Lifyorli by then.
